United Kingdom · Question · Written question
UIN 195969
Voluntary Scheme for Branded Medicines Pricing and Access: Life Sciences
Introduced
1 September 2023
Last action
11 September 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
11 September 2023
Summary
To ask the Secretary of State for Science, Innovation and Technology, whether she has made an assessment of potential links between the Voluntary Scheme for Branded Medicines Pricing and Access and levels of foreign direct investment in life sciences.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
1 September 2023
Written question
To ask the Secretary of State for Science, Innovation and Technology, whether she has made an assessment of potential links between the Voluntary Scheme for Branded Medicines Pricing and Access and levels of foreign direct investment in life sciences.
Source: Commons
11 September 2023
Answer
The Government has considered in broad terms the link between volume-based rebate payments in our medicine pricing schemes and various kinds of investment in our Impact Assessment of updates to the Statutory Scheme for branded medicines pricing, which ope...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department for Science, Innovation and Technology · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-09-01/195969
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1655860
- uk · wq-1655860 · source updated 11 September 2023